Moderna to Release Cancer Vaccine Trial Results, Joins Nasdaq-100

• Moderna is about to release trial results for its cancer vaccine this weekend.
• Moderna has been one of the hottest stocks of the year due to its custom cancer treatment.
• Earlier this month, Nasdaq Inc. added Moderna to its Nasdaq-100 index.
• The Nasdaq-100 index tracks the performance of the Nasdaq's 100 largest listings excluding the financial sector.
• The addition to the Nasdaq-100 index is a significant milestone for Moderna as a prospective investment.